Literature DB >> 15159026

A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer.

Hannes M Müller1, Andreas Widschwendter, Heidi Fiegl, Georg Goebel, Annemarie Wiedemair, Elisabeth Müller-Holzner, Christian Marth, Martin Widschwendter.   

Abstract

Promoter hypermethylation has been recognized to play an important role in carcinogenesis. We analyzed the methylation status of 25 genes in 14 normal cervical tissue specimens and in 65 tissue specimens from cervical cancer patients using the MethyLight technique. Most of the analyzed genes have been shown to be methylated in various cancers. RB1 was never methylated in any analyzed cervical tissue. DNA methylation status of the remaining 24 genes in every tissue sample was subsequently analyzed using unsupervised agglomerative hierarchical cluster analysis to group specimens and CpG regions. We observed four clusters. All normal cervical tissue specimens were grouped together in one cluster. Neither grade, nor histological type nor age demonstrated any significant association with clusters formed. Interestingly, statistically significantly less patients whose tumor DNA methylation pattern clustered together with normal cervical tissue died within our observation period, as compared to those patients out of the three remaining clusters (P < 0.03) Cervical cancer patients, whose DNA methylation pattern clustered together with normal cervical tissue revealed a strong trend to better survival (P = 0.066) compared to patients grouped in the remaining cluster. This study shows for the first time that working solely with DNA methylation pattern a subgroup of cervical cancer patients can be defined that demonstrated strong similarity to non-neoplastic probands and had a better prognosis. Copyright 2004 Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15159026     DOI: 10.1016/j.canlet.2003.12.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia.

Authors:  Divya A Patel; Laura S Rozek; Justin A Colacino; Adrienne Van Zomeren-Dohm; Mack T Ruffin; Elizabeth R Unger; Dana C Dolinoy; David C Swan; Juanita Onyekwuluje; Cecilia R DeGraffinreid; Electra D Paskett
Journal:  J Virol Methods       Date:  2012-06-01       Impact factor: 2.014

2.  Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.

Authors:  Yoon Hee Cho; Jing Shen; Marilie D Gammon; Yu-Jing Zhang; Qiao Wang; Karina Gonzalez; Xinran Xu; Patrick T Bradshaw; Susan L Teitelbaum; Gail Garbowski; Hanina Hibshoosh; Alfred I Neugut; Jia Chen; Regina M Santella
Journal:  Breast Cancer Res Treat       Date:  2011-08-12       Impact factor: 4.872

3.  Loss of estrogen receptor 1 enhances cervical cancer invasion.

Authors:  Yali Zhai; Guido T Bommer; Ying Feng; Alexandra B Wiese; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2010-06-25       Impact factor: 4.307

4.  Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation.

Authors:  Philipp Schatz; Dimo Dietrich; Thomas Koenig; Matthias Burger; Antje Lukas; Ina Fuhrmann; Glen Kristiansen; Robert Stoehr; Matthias Schuster; Ralf Lesche; Gunter Weiss; John Corman; Arndt Hartmann
Journal:  J Mol Diagn       Date:  2010-03-19       Impact factor: 5.568

Review 5.  Epigenetics of cervical cancer. An overview and therapeutic perspectives.

Authors:  Alfonso Dueñas-González; Marcela Lizano; Myrna Candelaria; Lucely Cetina; Claudia Arce; Eduardo Cervera
Journal:  Mol Cancer       Date:  2005-10-25       Impact factor: 27.401

6.  A novel method to quantify local CpG methylation density by regional methylation elongation assay on microarray.

Authors:  Dingdong Zhang; Yan Wang; Yunfei Bai; Qinyu Ge; Yingjuan Qiao; Junfeng Luo; Chao Jia; Zuhong Lu
Journal:  BMC Genomics       Date:  2008-01-31       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.